ERBB2 and cancer: It is more common in premenopausal women and almost twice as common in African-American women as compared with Caucasian women in USA.1,4,5 Luminal A, Luminal B and HER2-enriched cancers can be targeted using hormone- and HER2-targeting therapies such as trastuzumab or lapatinib.